Recursion Pharmaceuticals, Inc. (RXRX) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-25
Business type: Asset play
How it makes money
It earns upfront and milestone payments from large biopharmaceutical partners and anticipates future revenue from commercializing its own drug candidates.
Recursion operates as a clinical-stage TechBio company that has not yet generated any revenue from commercial drug product sales. Instead, it earns capital through strategic collaborations and partnerships with major biopharmaceutical companies such as Roche, Genentech, and Sanofi. These partners pay upfront fees and milestone payments for data generation, novel biological maps, and the advancement of AI-designed small molecule programs.
Looking forward, the company's long-term business model depends on successfully developing its proprietary internal pipeline of drug candidates through clinical trials and ultimately achieving regulatory approval to commercialize therapeutic products. Until then, its incoming cash flows rely entirely on the progression of partnered research programs and additional external financing arrangements.
What protects it: the moat
Management claims its proprietary Recursion Operating System and integrated end-to-end platform protect its competitive position in drug discovery.
The company relies heavily on the assertion that its proprietary technology platform—the Recursion Operating System (OS)—provides a distinct advantage in navigating disease space, generating biological data, and synthesizing molecules faster and more efficiently than traditional methods. Management states that this integrated, AI-native infrastructure allows it to translate complex science into differentiated internal programs and strategic partnerships.
However, the filing explicitly notes that the benefits of these artificial intelligence and machine learning technologies remain subject to ongoing validation and proof-of-concept. Because the company has no approved products on the market, these technological differentiators function as management's strategic claims rather than established commercial moats defended by commercial sales or regulatory exclusivity.
What growth costs
It reinvests heavily into research and development, preclinical and clinical testing, and general operations while accumulating substantial operating losses.
Maintaining and growing the business requires continuous, high-volume capital reinvestment. The company directs substantial financial resources into research and development efforts, which include building out the drug discovery platform, synthesizing novel compounds, and executing preclinical and clinical trials for its internal pipeline.
In addition to direct R&D expenditures, the company incurs ongoing general and administrative costs associated with operating as a public company. Because drug development is an expensive, multi-year undertaking, management expects these operating expenses to increase significantly as it advances existing candidates and initiates new clinical studies, necessitating regular supplemental funding.
What could damage it
An inability to raise substantial additional capital would force it to delay or eliminate development programs and potentially cease operations.
The company's entire operating model depends on continuous external funding to sustain its extensive preclinical and clinical pipeline until any product can be commercialized. If it fails to secure adequate financing on favorable terms when needed, management would be forced to halt or scale back its research operations. This restriction in funding would directly impair its ability to advance drug candidates through clinical trials, fulfill partner obligations, and ultimately achieve the product approvals required to generate future earnings.
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.